Currently, there are 45.68M common shares owned by the public and among those 40.15M shares have been available to trade.
The company’s stock has a 5-day price change of -25.46% and -18.72% over the past three months. CAPR shares are trading 66.45% year to date (YTD), with the 12-month market performance down to -44.64% lower. It has a 12-month low price of $3.52 and touched a high of $23.40 over the same period. CAPR has an average intraday trading volume of 2.62 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -26.97%, -26.77%, and -44.44% respectively.
Institutional ownership of Capricor Therapeutics Inc (NASDAQ: CAPR) shares accounts for 40.28% of the company’s 45.68M shares outstanding.
It has a market capitalization of $349.21M and a beta (3y monthly) value of 0.61. The earnings-per-share (ttm) stands at -$1.42. Price movements for the stock have been influenced by the stock’s volatility, which stands at 12.27% over the week and 15.66% over the month.
Earnings per share for the fiscal year are expected to increase by 13.83%, and 66.50% over the next financial year.
Looking at the support for the CAPR, a number of firms have released research notes about the stock. Alliance Global Partners stated their Buy rating for the stock in a research note on June 30, 2025, with the firm’s price target at $20. B. Riley Securities coverage for the Capricor Therapeutics Inc (CAPR) stock in a research note released on June 26, 2025 offered a Buy rating with a price target of $21. Roth Capital was of a view on May 20, 2025 that the stock is Buy, while Piper Sandler gave the stock Overweight rating on October 21, 2024, issuing a price target of $35. Oppenheimer on their part issued Outperform rating on May 17, 2024.
